Difference between revisions of "Lipefilgrastim (Lonquex)"
Jump to navigation
Jump to search
m |
m |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
From NCI: "A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation." | From NCI: "A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation." | ||
| − | [[Category: | + | ==History of changes in EMA indication== |
| − | [[Category: | + | *2013-07-25: Initial authorization |
| + | ==Also known as== | ||
| + | *'''Code name:''' XM22 | ||
| + | *'''Brand name:''' Lonquex | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Pegylated medications]] | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
[[Category:Granulocyte colony-stimulating factors]] | [[Category:Granulocyte colony-stimulating factors]] | ||
| − | [[Category: | + | [[Category:Recombinant medications]] |
| + | |||
| + | [[Category:EMA approved in 2013]] | ||
| + | [[Category:Stub]] | ||
Latest revision as of 14:34, 28 February 2024
Mechanism of action
From NCI: "A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation."
History of changes in EMA indication
- 2013-07-25: Initial authorization
Also known as
- Code name: XM22
- Brand name: Lonquex